Thakkar Umang G, Vanikar Aruna V, Trivedi Hargovind L
Department of Regenerative Medicine and Stem Cell Therapy and Pediatrics, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases & Research Centre (IKDRC), Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS), India.
Department of Regenerative Medicine and Stem Cell Therapy and Pediatrics, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases & Research Centre (IKDRC), Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS), India; Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases & Research Centre (IKDRC), Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS), India.
Diabetes Res Clin Pract. 2017 Aug;130:130-132. doi: 10.1016/j.diabres.2017.04.014. Epub 2017 Apr 19.
Stem cell based strategies are therapeutically potent for treating type-1 diabetes mellitus owing to their intrinsic regenerative capacity and immunomodulatory properties to arrest autoimmune β-cell destruction, preserve residual β-cell mass, facilitate endogenous regeneration, ameliorate innate/ alloimmune graft rejection, restore β-cell-specific unresponsiveness in absence of chronic immunosuppression and to reverse hyperglycemia.
基于干细胞的策略在治疗1型糖尿病方面具有治疗潜力，这归因于它们固有的再生能力和免疫调节特性，能够阻止自身免疫性β细胞破坏、保留残余β细胞量、促进内源性再生、改善先天性/同种免疫移植排斥反应、在无慢性免疫抑制的情况下恢复β细胞特异性无反应性并逆转高血糖。
